English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 28 February 2022, 18:29 HKT/SGT
Share:
    

Source: EC Healthcare
Senior Management Further Increases Shareholdings in EC Healthcare With Strong Confidence in the Group's Future Development

HONG KONG, Feb 28, 2022 - (ACN Newswire) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce that the Group's Chairman, Executive Director and Chief Executive Officer Mr. Tang Chi Fai further increases the shareholdings post the equity stake increase announced on January 17. Mr. Tang acquired a total 605,000 shares of the Company on the market for an aggregate consideration of approximately HK$ 4.96 million. On January 21, Mr. Tang acquired a total of 62,000 shares at an average price of approximately HK$8.49 per share and acquired a total of 543,000 shares at an average price of approximately HK$8.18 on January 22. After the transaction, Mr. Tang's equity stake in the Group increased to 60.39%

In the past year, EC Healthcare has actively integrated the healthcare market through organic growth and acquisitions to further consolidate leading market position. As the epidemic has raged on in Hong Kong now, the Group also actively provides anti-epidemic medical services to the public through its general outpatient clinics, specialist clinics, health check centers, vaccine centers and laboratory centers. Looking forward, the Group remain confident for the long-term strong business growth momentum and will keep investing in IT, brand and service to provide better services to the public."

About EC Healthcare
EC Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism. The Group is a constituent stock of Hang Seng Composite Index and the MSCI Hong Kong Small Cap Index.

The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, primary care clinics jointly established with Tencent Doctorwork, chiropractic services centre New York Spine and Physiotherapy Center NYMG, health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, a comprehensive dental centre UMH DENTAL CARE, a diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic SPECIALISTS CENTRAL, NEW MEDICAL CENTER and Prime Medical Centres, obstetrics and gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, specialists central, a paediatric center PRIME CARE, cardiology center HONG KONG INTERNATIONAL CARDIOLOGY CENTER, PathLab Medical Laboratories, a professional hair care center HAIR FOREST, Ophthalmology Center VIVID EYE and EC Veterinary Hospital and Imaging Center.

*According to independent research conducted by Frost and Sullivan in terms of revenue in 2019 and 2020


Topic: Press release summary
Source: EC Healthcare

Sectors: BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

EC Healthcare Related News
Nov 24, 2022 13:04 HKT/SGT
医思健康公布2022/23年度中期业绩 医疗服务业务推动收入同比增长31.1%
Nov 24, 2022 13:03 HKT/SGT
醫思健康公佈2022/23年度中期業績 醫療服務業務推動收入同比增長31.1%
Nov 24, 2022 13:02 HKT/SGT
EC Healthcare Announces FY2022/23 Interim Results, Revenue Increased 31.1% YoY Mainly Driven by Medical Services
Oct 17, 2022 08:50 HKT/SGT
医思健康料23上半财年销售额创新高至不少于18亿港元 按年升不少于17%
Oct 17, 2022 08:49 HKT/SGT
醫思健康料23上半財年銷售額創新高至不少於18億港元 按年升不少於17%
More news >>
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575